NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for...
Scopus BioPharma Inc (NASDAQ: SCPS) has acquired Los Angeles-based Olimmune Inc for an undisclosed amount.Olimmune is a developer of oligonucleotide immunotherapies for...
Scopus BioPharma Inc. is a biotechnology company. The Company is focused on developing therapeutics targeting serious diseases. The Company’s lead program targets immuno-oncology gene therapy for the treatment of multiple cancers. Its lead development program is CpG-STAT3siRNA (CO-sTiRNA), which is in Phase I clinical trial, is a STAT3 inhibitor gene therapy. CO-sTiRNA is developed for the treatment of B-cell non-Hodgkins lymphoma. It also stimulates TLR9 receptors to activate the body’s immune defense to kill cancer cells. Its second development program is in pre-clinical stage MRI-1867, a cannabinoid receptor mediating compound for the treatment of systemic sclerosis. MRI-1867 is a small molecule that is an inverse agonist of the cannabinoid-1 receptor (CB1), as well as an inhibitor of the inducible nitric oxide synthase (iNOS) system.